TY - JOUR
T1 - High-dose chemotherapy for breast cancer
T2 - Is another look warranted?
AU - Nieto, Yago
AU - Jones, Roy B.
AU - Shpall, Elizabeth J.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2004/3
Y1 - 2004/3
N2 - Purpose of review: Controversy has surrounded the use of high-dose chemotherapy for breast cancer for more than a decade. Numerous randomized trials have compared high-dose chemotherapy with standard-dose chemotherapy in metastatic breast cancer and high-risk primary breast cancer, defined by extensive axillary node involvement or inflammatory disease. The authors review the main research results of high-dose chemotherapy for breast cancer in 2002 to 2003. Recent findings: Preliminary analyses of three randomized trials in metastatic breast cancer and seven in high-risk primary breast cancer have been reported during this period. An advantage in event-free survival has been observed in all three studies in metastatic disease and in four of the high-risk primary cancer trials, albeit with no impact on overall survival at short follow-up. These early results are consistent with the most recent Cochrane reviews, which included trials reported through mid 2002. Summary: An early event-free survival advantage is apparent in favor of high-dose chemotherapy in both high-risk primary and metastatic breast cancer. Longer follow-up of those and most other trials is required to detect translation of the event-free survival differences into benefits in overall survival. High-dose chemotherapy remains a valid research strategy in event-free survival and high-risk primary breast cancer.
AB - Purpose of review: Controversy has surrounded the use of high-dose chemotherapy for breast cancer for more than a decade. Numerous randomized trials have compared high-dose chemotherapy with standard-dose chemotherapy in metastatic breast cancer and high-risk primary breast cancer, defined by extensive axillary node involvement or inflammatory disease. The authors review the main research results of high-dose chemotherapy for breast cancer in 2002 to 2003. Recent findings: Preliminary analyses of three randomized trials in metastatic breast cancer and seven in high-risk primary breast cancer have been reported during this period. An advantage in event-free survival has been observed in all three studies in metastatic disease and in four of the high-risk primary cancer trials, albeit with no impact on overall survival at short follow-up. These early results are consistent with the most recent Cochrane reviews, which included trials reported through mid 2002. Summary: An early event-free survival advantage is apparent in favor of high-dose chemotherapy in both high-risk primary and metastatic breast cancer. Longer follow-up of those and most other trials is required to detect translation of the event-free survival differences into benefits in overall survival. High-dose chemotherapy remains a valid research strategy in event-free survival and high-risk primary breast cancer.
KW - Autologous hematopoietic progenitor cell transplant
KW - High-dose chemotherapy
KW - High-risk primary breast cancer
KW - Metastatic breast cancer
UR - http://www.scopus.com/inward/record.url?scp=1642488234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642488234&partnerID=8YFLogxK
U2 - 10.1097/00001622-200403000-00005
DO - 10.1097/00001622-200403000-00005
M3 - Review article
C2 - 15075901
AN - SCOPUS:1642488234
SN - 1040-8746
VL - 16
SP - 114
EP - 119
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 2
ER -